These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells. Binda MM; Matar P; González AD; Rozados VR; Gervasoni SI; Scharovsky OG; Bonfil RD Int J Cancer; 2002 Jul; 100(1):14-21. PubMed ID: 12115581 [TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids. van Tilborg AA; Sweep FC; Geurts-Moespot AJ; Wetzels AM; de Waal RM; Westphal JR; Massuger LF Int J Oncol; 2014 Apr; 44(4):1394-400. PubMed ID: 24535412 [TBL] [Abstract][Full Text] [Related]
5. Thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen. Ramsden JD; Yarram S; Mathews E; Watkinson JC; Eggo MC J Endocrinol; 2002 Jun; 173(3):475-81. PubMed ID: 12065237 [TBL] [Abstract][Full Text] [Related]
6. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Gately S; Twardowski P; Stack MS; Cundiff DL; Grella D; Castellino FJ; Enghild J; Kwaan HC; Lee F; Kramer RA; Volpert O; Bouck N; Soff GA Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10868-72. PubMed ID: 9380726 [TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells. O'Mahony CA; Albo D; Tuszynski GP; Berger DH Surgery; 1998 Aug; 124(2):388-93. PubMed ID: 9706163 [TBL] [Abstract][Full Text] [Related]
8. [Mechanism of inhibitory effect of angiostatin on plasminogen activation by its physiologic activators]. Aĭsina RB; Mukhametova LI; Prisiazhnaia NV; Gulin DA; Levashov MIu; Gershkovich KB Bioorg Khim; 2011; 37(3):319-26. PubMed ID: 21899046 [TBL] [Abstract][Full Text] [Related]
9. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Gately S; Twardowski P; Stack MS; Patrick M; Boggio L; Cundiff DL; Schnaper HW; Madison L; Volpert O; Bouck N; Enghild J; Kwaan HC; Soff GA Cancer Res; 1996 Nov; 56(21):4887-90. PubMed ID: 8895739 [TBL] [Abstract][Full Text] [Related]
10. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Westphal JR; Van't Hullenaar R; Peek R; Willems RW; Crickard K; Crickard U; Askaa J; Clemmensen I; Ruiter DJ; De Waal RM Int J Cancer; 2000 Jun; 86(6):768-76. PubMed ID: 10842189 [TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. de Groot-Besseling RR; Ruers TJ; van Kraats AA; Poelen GJ; Ruiter DJ; de Waal RM; Westphal JR Int J Cancer; 2004 Nov; 112(2):329-34. PubMed ID: 15352048 [TBL] [Abstract][Full Text] [Related]
12. A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product. Mulligan-Kehoe MJ; Wagner R; Wieland C; Powell R J Biol Chem; 2001 Mar; 276(11):8588-96. PubMed ID: 11113116 [TBL] [Abstract][Full Text] [Related]
13. The accumulation of angiostatin-like fragments in human prostate carcinoma. Migita T; Oda Y; Naito S; Morikawa W; Kuwano M; Tsuneyoshi M Clin Cancer Res; 2001 Sep; 7(9):2750-6. PubMed ID: 11555588 [TBL] [Abstract][Full Text] [Related]
14. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines. Buø L; Bjørnland K; Karlsrud TS; Kvale D; Kjønniksen I; Fodstad O; Brandtzaeg P; Johansen HT; Aasen AO Anticancer Res; 1994; 14(6B):2445-51. PubMed ID: 7872665 [TBL] [Abstract][Full Text] [Related]
15. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. O'Reilly MS; Wiederschain D; Stetler-Stevenson WG; Folkman J; Moses MA J Biol Chem; 1999 Oct; 274(41):29568-71. PubMed ID: 10506224 [TBL] [Abstract][Full Text] [Related]
17. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. Meissauer A; Kramer MD; Hofmann M; Erkell LJ; Jacob E; Schirrmacher V; Brunner G Exp Cell Res; 1991 Feb; 192(2):453-9. PubMed ID: 1899072 [TBL] [Abstract][Full Text] [Related]
18. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. Scapini P; Nesi L; Morini M; Tanghetti E; Belleri M; Noonan D; Presta M; Albini A; Cassatella MA J Immunol; 2002 Jun; 168(11):5798-804. PubMed ID: 12023382 [TBL] [Abstract][Full Text] [Related]
19. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Meissauer A; Kramer MD; Schirrmacher V; Brunner G Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956 [TBL] [Abstract][Full Text] [Related]